Monoamine oxidase-B inhibition in Alzheimer's disease
Monoamine oxidase-B inhibition in Alzheimer's disease
复制标题
DOI：
10.1016/s0161-813x(03)00106-2
复制
发表时间：
2004-01-01
期刊：
影响因子：
3.4
通讯作者：
Grünblatt, E
中科院分区：
文献类型：
--
作者：
Riederer, P;Danielczyk, W;Grünblatt, E
阿尔茨海默病(AD)是老年痴呆最常见的原因。目前还没有明确的共识，这种疾病是与遗传因素还是环境因素有关，还是两者兼而有之。非常需要找到一种方法来推迟疾病的发生，因为推迟疾病的发病将给社会和医疗资源带来极大的缓解。单胺氧化酶-B(MAO-B)抑制剂被证明在治疗帕金森氏病和可能的阿尔茨海默病方面有效，并伴随着延长寿命。本文就MAO-B抑制剂及其在阿尔茨海默病中的神经保护作用机制作一综述。(C)2003 Elsevier Inc.保留所有权利。
Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD. (C) 2003 Elsevier Inc. All rights reserved.